146 related articles for article (PubMed ID: 36697099)
1. Treatment of Human Pancreatic Cancers Following Local and Systemic Administration of Oncolytic Adenovirus Serotype 35.
Ono R; Takayama K; Onishi R; Tokuoka S; Sakurai F; Mizuguchi H
Anticancer Res; 2023 Feb; 43(2):537-546. PubMed ID: 36697099
[TBL] [Abstract][Full Text] [Related]
2. Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35.
Ono R; Takayama K; Sakurai F; Mizuguchi H
Mol Ther Oncolytics; 2021 Mar; 20():399-409. PubMed ID: 33614920
[TBL] [Abstract][Full Text] [Related]
3. Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus.
Ono R; Nishimae F; Wakida T; Sakurai F; Mizuguchi H
Sci Rep; 2022 Dec; 12(1):21560. PubMed ID: 36513733
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.
Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S
Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292
[TBL] [Abstract][Full Text] [Related]
5. Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model.
Chu QD; Sun G; Pope M; Luraguiz N; Curiel DT; Kim R; Li BD; Mathis JM
Surgery; 2012 Sep; 152(3):441-8. PubMed ID: 22853858
[TBL] [Abstract][Full Text] [Related]
6. Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo.
Doerner J; Sallard E; Zhang W; Solanki M; Liu J; Ehrke-Schulz E; Zirngibl H; Lieber A; Ehrhardt A
Mol Cancer Ther; 2022 Mar; 21(3):460-470. PubMed ID: 35027480
[TBL] [Abstract][Full Text] [Related]
7. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
8. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.
Hammer K; Kazcorowski A; Liu L; Behr M; Schemmer P; Herr I; Nettelbeck DM
Int J Cancer; 2015 Aug; 137(4):978-90. PubMed ID: 25604186
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.
Takagi-Kimura M; Yamano T; Tagawa M; Kubo S
Cancer Gene Ther; 2014 Mar; 21(3):126-32. PubMed ID: 24577130
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic adenovirus based on serotype 3.
Hemminki O; Bauerschmitz G; Hemmi S; Lavilla-Alonso S; Diaconu I; Guse K; Koski A; Desmond RA; Lappalainen M; Kanerva A; Cerullo V; Pesonen S; Hemminki A
Cancer Gene Ther; 2011 Apr; 18(4):288-96. PubMed ID: 21183947
[TBL] [Abstract][Full Text] [Related]
11. PTTG1 Enhances Oncolytic Adenovirus 5 Entry into Pancreatic Adenocarcinoma Cells by Increasing CXADR Expression.
Long L; Gao J; Zhang R
Viruses; 2023 May; 15(5):. PubMed ID: 37243239
[TBL] [Abstract][Full Text] [Related]
12. Species D Adenoviruses as Oncolytic Viral Vectors.
Bullard BL; Corder BN; Weaver EA
Viruses; 2020 Dec; 12(12):. PubMed ID: 33291224
[TBL] [Abstract][Full Text] [Related]
13. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.
Wong HH; Jiang G; Gangeswaran R; Wang P; Wang J; Yuan M; Wang H; Bhakta V; Müller H; Lemoine NR; Wang Y
Mol Ther; 2012 Feb; 20(2):306-16. PubMed ID: 22086234
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma.
Chen W; Wu Y; Liu W; Wang G; Wang X; Yang Y; Chen W; Tai Y; Lu M; Qian Q; Zhang Q; Chen G
Cancer Lett; 2011 Aug; 307(1):93-103. PubMed ID: 21504839
[TBL] [Abstract][Full Text] [Related]
15. Strong antitumor efficacy of a pancreatic tumor-targeting oncolytic adenovirus for neuroendocrine tumors.
Yamamoto Y; Nagasato M; Rin Y; Henmi M; Ino Y; Yachida S; Ohki R; Hiraoka N; Tagawa M; Aoki K
Cancer Med; 2017 Oct; 6(10):2385-2397. PubMed ID: 28941156
[TBL] [Abstract][Full Text] [Related]
16. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
[TBL] [Abstract][Full Text] [Related]
17. Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model.
Zhang Z; Krimmel J; Zhang Z; Hu Z; Seth P
Hum Gene Ther; 2011 Sep; 22(9):1137-42. PubMed ID: 21480822
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of the gorilla-derived HAdV-B AdV-lumc007 oncolytic adenovirus 'GoraVir' for the treatment of pancreatic ductal adenocarcinoma.
Bots STF; Harryvan TJ; Groeneveldt C; Kinderman P; Kemp V; van Montfoort N; Hoeben RC
Mol Oncol; 2024 May; 18(5):1245-1258. PubMed ID: 38037840
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice.
Ganesh S; Gonzalez-Edick M; Gibbons D; Waugh J; Van Roey M; Jooss K
Hum Gene Ther; 2009 Oct; 20(10):1201-13. PubMed ID: 19572803
[TBL] [Abstract][Full Text] [Related]
20. E1B-55kD-deleted oncolytic adenovirus armed with canstatin gene yields an enhanced anti-tumor efficacy on pancreatic cancer.
He XP; Su CQ; Wang XH; Pan X; Tu ZX; Gong YF; Gao J; Liao Z; Jin J; Wu HY; Man XH; Li ZS
Cancer Lett; 2009 Nov; 285(1):89-98. PubMed ID: 19481338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
